Genenta Science SpA ADR (GNTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Genenta Science SpA ADR stock (GNTA) is currently trading at $0.75. Analyst consensus price target for GNTA is $6.87. WallStSmart rates GNTA as Sell.
- GNTA PE ratio analysis and historical PE chart
- GNTA PS ratio (Price-to-Sales) history and trend
- GNTA intrinsic value — DCF, Graham Number, EPV models
- GNTA stock price prediction 2025 2026 2027 2028 2029 2030
- GNTA fair value vs current price
- GNTA insider transactions and insider buying
- Is GNTA undervalued or overvalued?
- Genenta Science SpA ADR financial analysis — revenue, earnings, cash flow
- GNTA Piotroski F-Score and Altman Z-Score
- GNTA analyst price target and Smart Rating
Genenta Science SpA ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Genenta Science SpA ADR (GNTA) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Genenta Science SpA ADR (GNTA) Key Strengths (1)
Trading at 1.06x book value, attractively priced
Supporting Valuation Data
Genenta Science SpA ADR (GNTA) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 14.49%
Micro-cap company with very limited liquidity and high volatility
Genenta Science SpA ADR (GNTA) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.06) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -60.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GNTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Genenta Science SpA ADR (GNTA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Genenta Science SpA ADR operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -5,522, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Genenta Science SpA ADR.
Bottom Line
Genenta Science SpA ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Genenta Science SpA ADR(GNTA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Genenta Science SpA, a clinical-stage biotechnology company, is dedicated to the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company is headquartered in Milan, Italy.